Superficial thrombophlebitis of the chest wall associated with anticardiolipin antibodies: Antiphospholipid syndrome or Mondor's disease? [1]

Lupus

Volumn 13, Issue 1, 2004, Pages 70-71

  Boehlen, Françoise ^a,b   Bader, Marlyse ^b   De Moerloose, Philippe ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b University Hospital ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING DISORDER; BREAST HYPERPLASIA; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; LETTER; MONDOR SYNDROME; OBESITY; PRIORITY JOURNAL; SUPERFICIAL THROMBOPHLEBITIS; THORAX WALL; THROMBOPHLEBITIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; THORACIC WALL; THROMBOPHLEBITIS; THROMBOSIS;

EID: 1642501069     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu481xx     Document Type: Letter

References (13)

1. Pugh CM, DeWitty RL. Mondor's disease. J Nat Med Assoc 1996; 88: 359-363.
2. Godoy JM, Godoy MF, Batigalia F, Braile DM. The association of Mondor's disease with protein S deficiency: case report and review of the literature. J Thromb Thrombolysis 2002; 13: 187-189.
3. Cooper R. Mondor's disease secondary to intravenous drug abuse. Arch Surg 1990; 125: 807-808.
4. Kikano GE, Caceres VM, Sebas JA. Superficial thrombophlebitis of the anterior chest wall (Mondor's disease). J Fam Pract 1991; 33: 643-644.
5. Bejanga BI. Mondor's disease: analysis of 30 cases. J R Coll Surg Edinb 1992; 37: 322-324.
6. Catania S, Zurrida S, Veronesi P, Galimberti V, Bono A, Pluchinotta A. Mondor's disease and breast cancer. Cancer 1992; 69: 2267-2270.
7. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
8. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-1027.
9. Reber G, Arvieux J, Comby E, Degenne D, de Moerloose P, Sanmarco M, Potron G. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thromb Haemostas 1995; 73: 444-451.
10. de Moerloose P, Wutschert R, Heinzmann M, Perneger T, Reber G, Bounameaux H. Superficial vein thrombosis of lower limbs: influence pf factor V Leiden, factor II G20210A and overweight. Thromb Haemost 1998; 80: 239-241.
11. Naldi L, Locati F, Marchesi L, Cortelazzo S, Finazzi G, Galli M et al. Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study. Ann Rheum Dis 1993; 52: 219-222.
12. Godoy JM, Batigalia F, Braile DM. Superficial thrombophlebitis and anticardiolipin antibodies-report of association. Angiology 2001; 52: 127-129.
13. Wester JP, Kuenen BC, Meuwissen OJ, de Maat CE. Mondor's disease as first thrombotic event in hereditary protein C deficiency and anticardiolipin antibodies. Neth J Med 1997; 50: 85-87.